VIR Earnings Date: Nov 4, 2026 (Estimated) — Vir Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is VIR's next earnings date?
Vir Biotechnology, Inc. (VIR) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.74 on revenue of $858,875.
How did VIR do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Vir Biotechnology, Inc. posted EPS of $0.47 versus the $0.33 estimate, a beat of 46.6%. Revenue was $238.9M against a $135.9M estimate. The stock's 1-day post-earnings move was -3.8%.
How much does VIR stock move after earnings?
VIR beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.7% (up or down) in the day after earnings.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.33 | 0.47 | -46.59% | $238.9M | ✅ Beat | -3.79% | -1.65% | +25.69% |
| 2026-05-06 | Q1 2026 | 0.38 | -0.85 | -323.68% | $-29,000 | ❌ Miss | -9.91% | -9.33% | -15.94% |
| 2026-02-23 | Q4 2025 | -0.47 | -0.31 | +34.04% | $64.1M | ✅ Beat | +27.73% | +25.71% | +15.34% |
| 2025-11-05 | Q3 2025 | -0.80 | -1.17 | -46.25% | $240,000 | ❌ Miss | -5.19% | +5.74% | +20.37% |
| 2025-08-06 | Q2 2025 | -0.72 | -0.80 | -11.11% | $1.2M | ❌ Miss | -14.37% | -10.04% | +3.74% |
| 2025-02-26 | Q4 2024 | -0.87 | -0.76 | +12.64% | $12.4M | ✅ Beat | -11.85% | -10.65% | -27.50% |
| 2024-10-31 | Q3 2024 | -1.05 | -1.56 | -48.57% | $2.4M | ❌ Miss | +23.63% | +30.44% | +8.81% |
| 2024-08-01 | Q2 2024 | -0.89 | -1.02 | -14.61% | $3.1M | ❌ Miss | -5.34% | -11.41% | -15.11% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $238.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| License And Collaboration Revenue | 100.0% | $238.9M | — | — | — | — | — |
| Grant | 0.0% | $11K | -94.0% | $1.1M | $1.2M | $183K | $305K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.